
Jamie P Dwyer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6416459/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 606-617.	11.4	482
2	Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae. New England Journal of Medicine, 2019, 380, 791-793.	27.0	140
3	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrology Dialysis Transplantation, 2020, 35, 1700-1711.	0.7	107
4	Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). American Journal of Kidney Diseases, 2018, 71, 352-361.	1.9	104
5	COVID-19 and the Inpatient Dialysis Unit. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 720-722.	4.5	77
6	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet, The, 2018, 392, 2269-2279.	13.7	70
7	Dose-Response and Efficacy of Ferric Citrate to Treat Hyperphosphatemia in Hemodialysis Patients: A Short-term Randomized Trial. American Journal of Kidney Diseases, 2013, 61, 759-766.	1.9	55
8	A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney International, 2022, 101, 174-184.	5.2	53
9	Concordance Between Blood Pressure in the Systolic Blood Pressure Intervention Trial and in Routine Clinical Practice. JAMA Internal Medicine, 2020, 180, 1655.	5.1	52
10	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1805-1815.	8.6	49
11	The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. American Journal of Kidney Diseases, 2015, 66, 479-488.	1.9	41
12	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation, 2019, 139, 366-375.	1.6	32
13	Kidney Dysfunction and Left Ventricular Assist Device Support: A Comprehensive Perioperative Review. CardioRenal Medicine, 2015, 5, 48-60.	1.9	29
14	Nonproteinuric Diabetic Nephropathy. Medical Clinics of North America, 2013, 97, 53-58.	2.5	27
15	Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes. JAMA Cardiology, 2021, 6, 801.	6.1	26
16	Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials. Heart, 2022, 108, 1281-1289.	2.9	18
17	Does Renal Dysfunction and Method of Bridging Support Influence Heart Transplant Graft Survival?. Annals of Thoracic Surgery, 2014, 98, 835-841.	1.3	17
18	Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants. PLoS ONE, 2018, 13, e0203305.	2.5	14

JAMIE P DWYER

#	Article	IF	CITATIONS
19	Multinephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center Experience. Journal of Cardiac Failure, 2022, 28, 21-31.	1.7	8
20	Evaluation of Renal Artery Stenosis in Dialysis Patients. Seminars in Dialysis, 2009, 22, 519-523.	1.3	7
21	Ferric citrate: a novel phosphate-binding agent. Expert Review of Endocrinology and Metabolism, 2013, 8, 13-19.	2.4	5
22	Effect of Intensive versus Standard BP Control on AKI and Subsequent Cardiovascular Outcomes and Mortality: Findings from the SPRINT EHR Study. Kidney360, 2022, 3, 1253-1262.	2.1	5
23	Membranous glomerulopathy with superimposed pauci-immune necrotizing crescentic glomerulonephritis. CKJ: Clinical Kidney Journal, 2012, 5, 587-590.	2.9	4
24	Optimizing Blood Pressure Control in Patients With Nondiabetic Glomerular Disease. Advances in Chronic Kidney Disease, 2014, 21, 200-204.	1.4	4
25	Guidelines and Straitjackets: Blood Pressure Targets in the Era of theÂEighth Joint National Committee. American Journal of Kidney Diseases, 2014, 63, 895-899.	1.9	2
26	We Give Too Much Intravenous Iron. Seminars in Dialysis, 2016, 29, 309-311.	1.3	2
27	Assessment of Blood Pressure: Techniques and Implications From Clinical Trials. Advances in Chronic Kidney Disease, 2019, 26, 87-91.	1.4	2
28	FP590FERRIC CITRATE (FC) AS A PHOSPHATE BINDER IN PERITONEAL DIALYSIS (PD). Nephrology Dialysis Transplantation, 2015, 30, iii270-iii270.	0.7	0
29	439. Iclaprim Use for Acute Bacterial Skin and Skin Structure Infection (ABSSSI) is Not Associated with Hyperbalemia: Phase 3 REVIVE Studies, Open Forum Infectious Diseases, 2019, 6, S218-S218	0.9	О